ReviewMolecular and clinical oncology2013
The proliferation marker thymidine kinase 1 in clinical use.
Review in Molecular and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.Breast cancer research and treatment · 2024Trial
- DNMT3B- SLC25A6 axis-mediated DNA methylation regulates ferroptosis to promote paclitaxel resistance in triple-negative breast cancer.Frontiers in cell and developmental biology · 2026Article
- Intraocular Tumors in Horses: Diagnosis, Tumor Classification, Oncologic Assessment and Therapy.Veterinary sciences · 2025Review
- Thymidine kinase 1 indicates resistance to immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Ternary Complex Components Responsible for Rapid LDL Internalization as Biomarkers for Breast Cancer Associated with Proliferation and Early Recurrence.Cancer research communications · 2025Article
- Immunotherapeutic efficacy of recombinant canine IL-15 as an adjunct to chemotherapy in canine lymphoma.Frontiers in veterinary science · 2025Article
- Diagnostic value of serum survivin, Ki-67 and thymidine kinase in dogs with nasal cavity disease.Frontiers in veterinary science · 2025Article
- Pan-cancer analysis reveals that TK1 promotes tumor progression by mediating cell proliferation and Th2 cell polarization.Cancer cell international · 2024Article
- Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles.Biochemistry and biophysics reports · 2024Article
- Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular carcinoma based on a large-scale, multicenter study.Journal of cancer research and clinical oncology · 2023Article
- Article
- Methylation status of TK1 correlated with immune infiltrates in prostate cancer.Frontiers in genetics · 2022Article
- Article
- Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma.BMC molecular and cell biology · 2021Article
- Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients.Journal of clinical medicine · 2021Article
- Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker.BMC veterinary research · 2021Article
- Clinical performance of a commercially available thymidine kinase 1 assay for diagnosis of lymphoma in 42 hospitalized horses (2017-2020).Journal of veterinary internal medicine · 2021Article
- Single-Cell Transcriptomics Identifies a Unique Entity and Signature Markers of Transit-Amplifying Cells in Human Corneal Limbus.Investigative ophthalmology & visual science · 2021Article
- Maternal high-fat diet disrupted one-carbon metabolism in offspring, contributing to nonalcoholic fatty liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- A potential panel of five mRNAs in urinary extracellular vesicles for the detection of bladder cancer.Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-related biomarkers are used for the diagnosis, prognosis and monitoring of treatments and follow-up of cancer patients, although only a few are fully accepted for the detection of invisible/visible tumors in health screening. Thymidine kinase 1 (TK1), a cell cycle-dependent and thus a proliferation-related marker, has been extensively studied during the last decades, using both biochemical and immunological techniques. Therefore, TK1 is an emerging potential proliferating biomarker in oncology that may be used for the prognosis and monitoring of tumor therapy, relapse and survival. In addition, TK1 concentration in serum (STK1p) is a useful biomarker in healthy screening for the detection of potential malignancy development as well as the identification of early-stage tumors, with a few false-positive cases (ROC value, 0.96; tumor proliferation sensitivity, 0.80; specificity, 0.99). In this review, we examine results regarding the expression of STK1p and TK1 in relation to cancer patients and STK1p in health screening published between 2000 and 2012. The use of tumor-related markers recommended by international cancer organizations is also discussed. This review provides valuable information for applications in tumor patients, in health screening and for cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.